1. 316 Phase I study of lurbinectedin (PM01183) in combination with cisplatin (C) with or without aprepitant (Ap) in patients (pts) with advanced solid tumors. (September 2015) Authors: Forster, M.; Sessa, C.; Von Moos, R.; Brown, N.; Metaxas, Y.; Griguolo, G.; Lardelli, P.; Coronado, C.; Juan, L.; Fernandez-Teruel, C.; Soto-Matos, A.; Stathis, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Mathematical modeling of oral absorption and bioavailability of a fluoroquinolone after its precipitation in the gastrointestinal tract. (8th January 2013) Authors: Fernandez-Teruel, C.; Mangas-Sanjuan, V.; Gonzalez-Alvarez, I.; Ruiz-Garcia, A.; Casabó, V. G.; Bermejo, M. Journal: Xenobiotica Issue: Volume 43:Number 9(2013:Sep.) Page Start: 745 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase I study of lurbinectedin (PM01183) in combination with cisplatin (CDDP) with or without aprepitant in patients (pts) with advanced solid tumors. (February 2017) Authors: Forster, M.; Sessa, C.; Von Moos, R.; Brown, N.; Metaxas, Y.; Griguolo, G.; Lardelli, P.; Iglesias, J.; Fernandez-Teruel, C.; Jandali, U.; Soto-Matos, S.M.; Stathis, A. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S134 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗